Coherus BioSciences Inc CHRS:NASDAQ

Last Price$19.05NASDAQ Closing Price as of 4:00PM ET 5/20/19
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change+0.50(2.70%)
Bid (Size)$17.14 (1)
Ask (Size)$19.50 (1)
Day Low / High$17.99 - 19.31
Volume1.4 M

View Biotechnology IndustryPeer Comparison as of 05/20/2019


Coherus BioSciences Inc ( NASDAQ )

Price: $19.05
Change: +0.50 (2.70%)
Volume: 1.4 M
4:00PM ET 5/20/2019

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A

Momenta Pharmaceuticals Inc ( NASDAQ )

Price: $12.81
Change: -0.40 (3.03%)
Volume: 403.6 K
3:59PM ET 5/20/2019

OPKO Health Inc ( NASDAQ )

Price: $1.99
Change: -0.06 (2.93%)
Volume: 3.5 M
3:59PM ET 5/20/2019

Aimmune Therapeutics Inc ( NASDAQ )

Price: $19.65
Change: -0.46 (2.29%)
Volume: 440.7 K
4:00PM ET 5/20/2019

Read more news Recent News

Analyst Actions: HC Wainwright Starts Coherus BioSciences at Buy, With $28 Price Target
9:41AM ET 5/07/2019 MT Newswires

Coherus BioSciences' (CHRS) average rating among analysts is a buy, with an average price target of $30. Price: 16.48, Change: -0.23, Percent Change: -1.38...

Coherus BioSciences and Amgen Reach Settlement on Trade Secret Action
5:14AM ET 5/03/2019 MT Newswires

Coherus BioSciences (CHRS) said late Thursday that it has reached a settlement on a trade secret action brought by Amgen (AMGN) that was pending in the...

Coherus Expects $36-$38 Mln Q1 Sales of UDENYCA, Biosimilar to Amgen's Neulasta; Stock Up 5% After-Hours
4:18PM ET 4/05/2019 MT Newswires

Coherus BioSciences (CHRS) said on Friday UDENYCA preliminary net sales are expected to be in the range of $36 million to $38 million in Q1. The company...

Coherus BioSciences Details Equity Grants
12:03PM ET 3/19/2019 MT Newswires

Coherus BioSciences (CHRS) said Tuesday the compensation committee of the company's board granted the newly hired chief legal officer an option to buy...

Company Profile

Business DescriptionCoherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar, and Steve Glover in September 2010 and is headquartered in Redwood City, CA. View company web site for more details
Address333 Twin Dolphin Drive
Redwood City, California 94065
Number of Employees232
Recent SEC Filing05/09/20198-K
Chairman, President & Chief Executive OfficerDenny M. Lanfear
Chief Operating OfficerVincent R. Anicetti
Chief Financial OfficerJean-Frédéric Viret
Chief Technical OfficerPeter K. Watler

Company Highlights

Price Open$18.32
Previous Close$18.55
52 Week Range$8.32 - 20.66
Market Capitalization$1.3 B
Shares Outstanding69.3 M
SectorHealth Technology
Next Earnings Announcement08/14/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.68
Beta vs. S&P 500N/A
Net Profit Margin-498.80%
Return on Equity48,063.90%

Analyst Ratings as of 05/10/2019

Consensus RecommendationConsensus Icon
Powered by Factset